- Home
- ZGN vs RCKT Comparison
ZGN vs RCKT Comparison
Compare ZGN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGN | RCKT |
|---|---|---|
| Founded | 1910 | 1999 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 340.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZGN | RCKT |
|---|---|---|
| Price | $10.80 | $3.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $10.98 | ★ $29.12 |
| AVG Volume (30 Days) | 515.0K | ★ 2.1M |
| Earning Date | 09-05-2025 | 02-26-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $2,248,050,499.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.05 | $2.19 |
| 52 Week High | $11.00 | $13.30 |
Technical Indicators
Market Signals| Indicator | ZGN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 63.44 |
| Support Level | $10.29 | $3.36 |
| Resistance Level | $10.73 | $4.05 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 93.65 | 76.74 |
Price Performance
Historical ComparisonAbout ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.